ClinVar Miner

Submissions for variant NM_007194.4(CHEK2):c.915A>C (p.Glu305Asp)

gnomAD frequency: 0.00001  dbSNP: rs587780191
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 8
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000116032 SCV000149941 uncertain significance not provided 2023-07-26 criteria provided, single submitter clinical testing Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Identified in individuals with breast cancer and also in unaffected controls (Decker et al., 2017; Dorling et al., 2021); This variant is associated with the following publications: (PMID: 27443514, 33099347, 22419737, 19782031, 33471991, 28779002)
Ambry Genetics RCV000213975 SCV000275407 uncertain significance Hereditary cancer-predisposing syndrome 2023-09-13 criteria provided, single submitter clinical testing The p.E305D variant (also known as c.915A>C), located in coding exon 8 of the CHEK2 gene, results from an A to C substitution at nucleotide position 915. The glutamic acid at codon 305 is replaced by aspartic acid, an amino acid with highly similar properties. This alteration was reported as functional in a study assessing CHEK2-complementation through quantification of KAP1 phosphorylation and CHK2 autophosphorylation in human RPE1-CHEK2-knockout cells (Stolarova L et al. Clin Cancer Res, 2023 Aug;29:3037-3050). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Invitae RCV000473787 SCV000550463 uncertain significance Familial cancer of breast 2024-01-05 criteria provided, single submitter clinical testing This sequence change replaces glutamic acid, which is acidic and polar, with aspartic acid, which is acidic and polar, at codon 305 of the CHEK2 protein (p.Glu305Asp). This variant is present in population databases (rs587780191, gnomAD 0.003%). This missense change has been observed in individual(s) with endometrial cancer (PMID: 27443514). ClinVar contains an entry for this variant (Variation ID: 128088). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Color Diagnostics, LLC DBA Color Health RCV000213975 SCV000684698 uncertain significance Hereditary cancer-predisposing syndrome 2022-09-19 criteria provided, single submitter clinical testing This missense variant replaces glutamic acid with aspartic acid at codon 305 of the CHEK2 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been performed for this variant. This variant has been reported in individuals affected with breast and endometrial cancer in the literature (PMID: 27443514, 28779002) . In a large breast cancer case-control study, this variant has been observed in 3/60466 cases and 2/53461 unaffected controls (OR=1.326; 95%CI 0.222 to 7.938); p-value=1; Leiden Open Variation Database DB-ID CHEK2_000403) (PMID: 33471991). This variant has been identified in 5/282456 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV001251264 SCV001426782 uncertain significance not specified 2020-07-10 criteria provided, single submitter clinical testing Variant summary: CHEK2 c.915A>C (p.Glu305Asp) results in a conservative amino acid change located in the Protein kinase domain (IPR000719) of the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 1.6e-05 in 251072 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.915A>C has been reported in the literature as a VUS in at-least one individual affected with Endometrial cancer (Ring_2016). This report does not provide unequivocal conclusions about association of the variant with Hereditary Breast And Ovarian Cancer Syndrome. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance.
Genetic Services Laboratory, University of Chicago RCV001251264 SCV002068112 uncertain significance not specified 2020-05-01 criteria provided, single submitter clinical testing DNA sequence analysis of the CHEK2 gene demonstrated a sequence change, c.915A>C, in exon 9 that results in an amino acid change, p.Glu305Asp. This sequence change does not appear to have been previously described in patients with CHEK2 -related disorders and has been described in the gnomAD database with a low population frequency of 0.0018% (rs587780191). The p.Glu305Asp change affects a moderately conserved amino acid residue located in a domain of the CHEK2 protein that is known to be functional. In-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL) provide contradictory results for the p.Glu305Asp substitution. Due to these contrasting evidences and the lack of functional studies, the clinical significance of the p.Glu305Asp change remains unknown at this time.
Sema4, Sema4 RCV000213975 SCV002537653 uncertain significance Hereditary cancer-predisposing syndrome 2021-12-09 criteria provided, single submitter curation
Baylor Genetics RCV000473787 SCV004217498 uncertain significance Familial cancer of breast 2023-10-17 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.